7 completed, 1 not yet recruiting, 1 unknown. 5 Phase 2, 4 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
Follow netupitant: new trials by email Literature Review of netupitant trials Research Report on netupitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy Netupitant/Palonosetron Hydrochloride, Ondansetron (Control), Aprepitant - Germ Cell Cancer | Early Phase 1 | Not yet recruiting | Ottawa Hospital Research Institute | 10 | 2026-08-01 | 2026-06-23 |
| NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens Netupitant / Palonosetron Oral Capsule [Akynzeo], Olanzapine, Dexamethasone Oral - Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy | Phase 3 | Completed | Fudan University | 644 | 2024-05-01 | 2026-04-09 |
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer Olanzapine, Netupitant, Palonesetron - Nausea Post Chemotherapy | Phase 2 | Completed | Instituto Brasileiro de Controle do Cancer | 50 | 2020-12-17 | 2022-02-23 |
| Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride - Breast Carcinoma | Phase 3 | Completed | University of Rochester NCORP Research Base | 1363 | 2018-04-19 | 2025-09-25 |
| PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting Netupitant, Palonosetron - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 2 | Completed | Helsinn Healthcare SA | 67 | 2017-08-31 | 2024-06-25 |
| Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer Netupitant, Palonosetron, Palonosetron Hydrochloride - Malignant Neoplasm, Nausea | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 53 | 2017-05-03 | 2023-10-17 |
| Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant Netupitant, Palonosetron Hydrochloride, Questionnaire Administration - Malignant Neoplasm | Phase 2 | Completed | OHSU Knight Cancer Institute | 43 | 2017-04-27 | 2021-07-12 |
| Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin Netupitant/Palonosetron, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Unknown | Consorzio Oncotech | 261 | 2016-11-25 | 2020-04-03 |
| NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer Netupitant/Palonosetron - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Completed | Consorzio Oncotech | 150 | 2016-05-12 | 2019-03-05 |
Vomiting (5) · Nausea (4) · Breast Neoplasms (3) · Neoplasms (2) · Lung Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1)
Consorzio Oncotech (2) · Fudan University (1) · Helsinn Healthcare SA (1) · Instituto Brasileiro de Controle do Cancer (1) · M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1) · Ottawa Hospital Research Institute (1) · University of Rochester NCORP Research Base (1)
United States (4) · Brazil (1) · Canada (1) · China (1) · Italy (1) · Russia (1) · Serbia (1) · Ukraine (1)
David Hui (1) · Emilio Bria, MD (1) · Jian Zhang, MD,PhD (1) · Joseph Bubalo (1) · Luigi Celio, MD (1) · Luke Peppone (1) · Michelino De Laurentiis, MD, PhD (1)
PMID 32188417, PMID 33388382, PMID 35999527, PMID 36690734, PMID 37290207, PMID 38433125, PMID 40367007, PMID 42241642, PMID 42776270
R01CA200579 (1), UG1CA189961 (1)